ENTXHealthcare · BiotechnologyThe 5 Wall Street analysts covering Entera Bio Ltd. hold a median 12-month price target of $9.5 — +278.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 6 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Entera Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (75): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ENTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +278.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Guggenheim | Initiates | Buy | $11 |
| 25 Sept 2026 | Guggenheim | Initiates | Buy | — |
| 23 Sept 2026 | LifeSci Capital | Initiates | Outperform | $10 |
| 23 Sept 2026 | LifeSci Capital | Initiates | Outperform | — |
| 22 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 22 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Sept 2026 | Leerink Partners | Initiates | Outperform | $9.00 |
| 18 Sept 2026 | Leerink Partners | Initiates | Outperform | — |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.00 |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, Entera Bio Ltd. returned +32.8% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 1% of US stocks
Cheaper than 6% of US stocks
Cheaper than 92% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 10% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Entera Bio Ltd. has a market value of $442.3M and an enterprise value of $442.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.0M.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Trailing P/E: −10.2×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Entera Bio Ltd. employs 20 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Entera Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Entera Bio announced that biopharmaceutical executive Laura Hamill will join its Board of Directors, effective December 1, 2026.
Why it matters — The appointment adds a global biopharmaceutical executive to Entera’s board, expanding its commercial expertise.
Entera Bio announced that its CEO, Miranda Toledano, will participate in upcoming fall investor conferences. The announcement was made on August 27, 2026, via GlobeNewsWire and corrects a prior release.
Why it matters — An ENTX watcher would care because the CEO's participation in investor conferences provides the company with opportunities to present its oral peptide development pipeline to the investment community.
Entera Bio announced that CEO Miranda Toledano will participate in upcoming fall investor conferences, including a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 1:00 p.m.
Why it matters — The CEO's participation in investor conferences provides ENTX watchers with opportunities to hear directly from management about the company's oral peptide development program.
Entera Bio Ltd. announced the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer ahead of its planned EB613 Phase 3 initiation. Camisasca brings 30 years of global pharmaceutical research and clinical development experience from roles at Sumitomo Pharma, Takeda, and Novartis.
Why it matters — A watcher would care because the appointment strengthens Entera's clinical execution and late-stage development capabilities as the company prepares to initiate its planned EB613 Phase 3 trial.
Entera Bio has reached an agreement with the FDA on a 12-month, placebo-controlled registrational trial design for its oral osteoporosis drug candidate EB613, and plans to begin a Phase 3 study.
Why it matters — The FDA agreement clears a key regulatory path for EB613, moving Entera Bio's lead candidate closer to potential approval in the osteoporosis space.
The 5 Wall Street analysts covering Entera Bio Ltd. have a median 12-month price target of $9.5, with estimates ranging from $9 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Entera Bio Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entera Bio Ltd. 45 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Entera Bio Ltd. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (75 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +278.5% from the last close, and Ticker Nerd's factor model ranks Entera Bio Ltd. 45 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Entera Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $11 over the next 12 months.
Entera Bio Ltd. returned +32.8% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise". Entera Bio announced that biopharmaceutical executive Laura Hamill will join its Board of Directors, effective December 1, 2026.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered peptide and protein replacement therapies for serious unmet medical needs. Its work centers on converting complex therapies that are typically injected into mini-tablet formats designed for easier administration and improved patient adherence. The company’s technology platform supports oral delivery by stabilizing peptides in the gastrointestinal tract and enhancing absorption into the bloodstream. Entera Bio’s current pipeline includes programs targeting bone, endocrine, and metabolic disorders, with research spanning parathyroid hormone, GLP-1, and GLP-2-based therapies. The company also pursues collaborations and licensing opportunities to advance its oral drug delivery platform across selected therapeutic areas. Headquartered in Jerusalem, Israel, Entera Bio plays a specialized role in the biopharmaceutical market by addressing delivery challenges that limit the use of large-molecule medicines.
CEO Ms. Miranda J. Toledano M.B.A. · 20 employees · Israel · https://enterabio.com
